Literature DB >> 11682068

Agonist-independent and -dependent oligomerization of dopamine D(2) receptors by fusion to fluorescent proteins.

T Wurch1, A Matsumoto, P J Pauwels.   

Abstract

Oligomerization of the short (D(2S)) and long (D(2L)) isoforms of the dopamine D(2) receptor was explored in transfected Cos-7 cells by their C-terminal fusion to either an enhanced cyan or enhanced yellow fluorescent protein (ECFP or EYFP) and the fluorescent fusion protein interaction was monitored by a fluorescence resonance energy transfer (FRET) assay. The pharmacological properties of the fluorescent fusion proteins, as measured by both displacement of [(3)H]nemonapride binding and agonist-mediated stimulation of [(35)S]GTPgammaS binding upon co-expression with a G(alphao)Cys(351)Ile protein, were not different from the respective wild-type D(2S) and D(2L) receptors. Co-expression of D2S:ECFP+D2S:EYFP in a 1:1 ratio and D2L:ECFP+D2L:EYFP in a 27:1 ratio resulted, respectively, in an increase of 26% and 16% in the EYFP-specific fluorescent signal. These data are consistent with a close proximity of both D(2S) and D(2L) receptor pairs of fluorescent fusion proteins in the absence of ligand. The agonist-independent D(2S) receptor oligomerization could be attenuated by co-expression with either a wild-type, non-fluorescent D(2S) or D(2L) receptor subtype, but not with a distinct beta(2)-adrenoceptor. Incubation with the agonist (-)-norpropylapomorphine dose-dependently (EC(50): 0.23+/-0.06 nM) increased the FRET signal for the co-expression of D2S:ECFP and D2S:EYFP, in support of agonist-dependent D(2S) receptor oligomerization. In conclusion, our data strongly suggest the occurrence of dopamine D(2) receptor oligomers in intact Cos-7 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682068     DOI: 10.1016/s0014-5793(01)02969-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  Roles of G-protein-coupled receptor dimerization.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

Review 2.  Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells.

Authors:  Kevin D G Pfleger; Karin A Eidne
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

Review 3.  Oligomers of D2 dopamine receptors: evidence from ligand binding.

Authors:  Philip G Strange
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.

Authors:  Y Iris Chen; Ji-Kyung Choi; Haibo Xu; Jiaqian Ren; Susan L Andersen; Bruce G Jenkins
Journal:  Dev Neurosci       Date:  2010-06-03       Impact factor: 2.984

5.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Authors:  Pierre Savi; Jean-Luc Zachayus; Nathalie Delesque-Touchard; Catherine Labouret; Caroline Hervé; Marie-Françoise Uzabiaga; Jean-Marie Pereillo; Jean-Michel Culouscou; Françoise Bono; Pascual Ferrara; Jean-Marc Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

6.  Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-04-27

7.  Bioluminescence resonance energy transfer reveals the adrenocorticotropin (ACTH)-induced conformational change of the activated ACTH receptor complex in living cells.

Authors:  Sadani N Cooray; Teng-Teng Chung; Khansa Mazhar; Laszlo Szidonya; Adrian J L Clark
Journal:  Endocrinology       Date:  2010-12-22       Impact factor: 4.736

Review 8.  Contributions of fluorescence techniques to understanding G protein-coupled receptor dimerisation.

Authors:  Alan D Goddard; Anthony Watts
Journal:  Biophys Rev       Date:  2012-04-12

9.  Receptor oligomerization: from early evidence to current understanding in class B GPCRs.

Authors:  Stephanie Y L Ng; Leo T O Lee; Billy K C Chow
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-04       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.